Financial reports
ARS
2023 FY
Annual report to shareholders
26 Apr 24
10-K
2023 FY
Annual report
26 Feb 24
10-Q
2023 Q3
Quarterly report
9 Nov 23
10-Q
2023 Q2
Quarterly report
2 Aug 23
10-Q
2023 Q1
Quarterly report
4 May 23
ARS
2022 FY
Annual report to shareholders
27 Apr 23
10-K
2022 FY
Annual report
27 Feb 23
10-Q
2022 Q3
Quarterly report
9 Nov 22
10-Q
2022 Q2
Quarterly report
8 Aug 22
10-Q
2022 Q1
Quarterly report
9 May 22
Current reports
8-K
Results of Operations and Financial Condition
26 Apr 24
8-K
BeiGene Receives European Commission Approval for Tislelizumab as Treatment for Non-Small Cell Lung Cancer
23 Apr 24
8-K
Departure of Directors or Certain Officers
20 Mar 24
8-K
BeiGene Receives FDA Approval for TEVIMBRA® for the Treatment of Advanced or Metastatic Esophageal Squamous Cell Carcinoma After Prior Chemotherapy
15 Mar 24
8-K
Other Events
8 Mar 24
8-K
BeiGene Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates
26 Feb 24
8-K
BeiGene Welcomes Experienced Life Sciences Executive Olivier Brandicourt to Board of Directors
23 Jan 24
8-K
Other Events
8 Dec 23
8-K
BeiGene Continues Global Growth with Third Quarter 2023 Financial Results and Business Updates
9 Nov 23
8-K
BRUKINSA® Receives Positive Recommendation from NICE in U.K. for Adult Patients with Chronic Lymphocytic Leukemia
20 Oct 23
Registration and prospectus
S-3ASR
Automatic shelf registration
9 May 23
S-3ASR
Automatic shelf registration
9 May 23
S-8
Registration of securities for employees
8 Aug 22
424B5
Prospectus supplement for primary offering
1 Dec 21
424B5
Prospectus supplement for primary offering
23 Nov 21
424B7
Prospectus with selling stockholder info
2 Dec 20
424B7
Prospectus with selling stockholder info
1 Dec 20
S-8
Registration of securities for employees
6 Aug 20
424B2
Prospectus for primary offering
13 Jul 20
S-3ASR
Automatic shelf registration
11 May 20
Proxies
DEF 14A
Definitive proxy
26 Apr 24
PRE 14A
Preliminary proxy
15 Apr 24
DEF 14A
Definitive proxy
27 Apr 23
PRE 14A
Preliminary proxy
17 Apr 23
DEF 14A
Definitive proxy
29 Apr 22
PRE 14A
Preliminary proxy
18 Apr 22
DEF 14A
Definitive proxy
30 Apr 21
PRE 14A
Preliminary proxy
19 Apr 21
DEFA14A
Additional proxy soliciting materials
29 Jan 21
DEF 14A
Definitive proxy
9 Oct 20
Other
UPLOAD
Letter from SEC
7 Dec 23
CORRESP
Correspondence with SEC
4 Oct 23
UPLOAD
Letter from SEC
21 Sep 23
CORRESP
Correspondence with SEC
21 Aug 23
CORRESP
Correspondence with SEC
26 Jul 23
UPLOAD
Letter from SEC
21 Jul 23
UPLOAD
Letter from SEC
15 Jun 22
CORRESP
Correspondence with SEC
3 Jun 22
UPLOAD
Letter from SEC
20 May 22
CORRESP
Correspondence with SEC
6 May 22
Ownership
4
JOHN OYLER
11 Apr 24
144
Notice of proposed sale of securities
9 Apr 24
3
Titus B. Ball
26 Mar 24
144
Notice of proposed sale of securities
26 Mar 24
4
JOHN OYLER
14 Mar 24
4
Donald W. Glazer
13 Mar 24
144
Notice of proposed sale of securities
12 Mar 24
4
OLIVIER BRANDICOURT
4 Mar 24
4
Julia Aijun Wang
4 Mar 24
144
Notice of proposed sale of securities
29 Feb 24